Close menu




EVOTEC SE INH O.N.

Photo credits: pixabay.com

Commented by André Will-Laudien on May 9th, 2024 | 07:00 CEST

Biotech and pharma stocks finally follow suit! Novo Nordisk, Bayer, BioNTech, Vidac Pharma and Evotec on the buy list

  • Biotechnology
  • Pharma

Things looked very different at the beginning of the year. After a brilliant rally in the Nasdaq Biotech Index at the end of last year, investors thought the upswing could continue in 2024. So far, this hope has not been confirmed. The main focus for the industry is the refinancing conditions. These have gradually deteriorated, as stubborn inflation is keeping central bank interest rates high. And judging by the wording of central bankers, the next interest rate cut does not seem to be penciled in yet. However, if it happens in the summer, things will likely move quickly for the life sciences sector. Then a quick sector rotation is the order of the day! Here is our buy list for the upcoming event.

Read

Commented by Fabian Lorenz on May 8th, 2024 | 06:45 CEST

BUY RECOMMENDATIONS! Are Evotec, Super Micro Computer, and Royal Helium about to take off?

  • Mining
  • Helium
  • AI
  • Biotechnology

Evotec's share price has plummeted by around 50% this year. Consequently, the stock is among the year's losers. However, several buy recommendations are raising eyebrows. Is the turnaround imminent? The Royal Helium share is also ripe for a turnaround. The little-known noble gas is used in the defense industry, medical technology and for quantum computers, among other things. Royal Helium aims to transition from an explorer into a producer and has enlisted strong partners to achieve this. Will the share see a breakthrough after the ongoing capital increase? And what about Super Micro Computer? The AI high-flyer seems to have overcome its phase of weakness. Is it now heading for new all-time highs?

Read

Commented by André Will-Laudien on May 2nd, 2024 | 06:45 CEST

Is it time already? Get out of AI, and buy biotech: Nvidia, Evotec, Defence Therapeutics and Bayer in focus

  • Biotechnology
  • Pharma
  • AI

Another blow to the bottom line! At the end of April, the Nasdaq technology exchange plummeted for the third time, again showing significant weakness at 17,333 points. After a long upward trend of the NDX to just under 18,500 points, an upper limit seems to have been found. Even high-tech favorites such as Nvidia, Super Micro, Meta, and Apple show dangerous reversal points on the chart. At the same time, some stocks in the biotech sector are forming good bottom formations. Is now the time to switch?

Read

Commented by Armin Schulz on April 30th, 2024 | 07:00 CEST

Evotec, Vidac Pharma, BioNTech - The billion-dollar race for cancer therapy

  • Biotechnology
  • Pharma
  • Cancer

Oncology is on the brink of a golden era. Driven by an increase in cancer cases and impressive scientific advances, including gene and immunotherapies, a billion-dollar market with immense growth prospects is emerging. The increasing demand for personalized medicines and the rapid development of new forms of therapy through technological progress are driving revenues in the pharmaceutical industry. This not only underlines the enormous financial value of oncology as an investment area but also promises ground-breaking improvements in patient care. We look at three companies that could benefit from this.

Read

Commented by Fabian Lorenz on April 23rd, 2024 | 07:00 CEST

TAKEOVER FEVER for biotech shares! Evotec, Bayer, Vidac Pharma - Who will follow Morphosys?

  • Biotechnology
  • Pharma
  • Innovations
  • Cancer

There is takeover fever in the biotech sector. Genmab recently announced the acquisition of ProfoundBio, the US biotech company developing ovarian and endometrial cancer drugs, for USD 1.8 billion. With Morphosys, the takeover carousel is also turning in Germany. Who is the next candidate? Evotec is often mentioned. Due to unauthorized insider trading, the biotech company's shares have come under fire this year and offer an interesting entry opportunity. Vidac Pharma also impresses operationally. The Company's new approach has the potential to revolutionize cancer treatment. The study results of the past few months are very promising. Bayer shares surprised investors yesterday as one of the day's winners in the DAX. Is the Leverkusen-based company's stock about to take off?

Read

Commented by Juliane Zielonka on April 12th, 2024 | 07:00 CEST

AI in healthcare with Evotec, Defence Therapeutics, Bayer: Revolutionary advances and medical breakthroughs

  • Biotechnology
  • Pharma
  • AI

Artificial intelligence (AI) is gaining momentum in the healthcare sector. AI-based systems can use medical databases to save valuable time in research, enabling companies like Defence Therapeutics to go to market faster than others. In oncology research, the Canadian company has just achieved a breakthrough that gives hope to many cancer patients. AI-assisted diagnoses allow diseases to be detected earlier and treated more effectively, leading to improved quality of life for patients. Precision medicine in strong partnership networks is Evotec's focus. The share is particularly popular with hedge fund managers. Analyzing medical images and data in real-time and detecting even the smallest deviations or anomalies is the top priority for Bayer AG in collaboration with Google Cloud. Which companies are convincing investors the most?

Read

Commented by Armin Schulz on March 28th, 2024 | 08:45 CET

TUI, dynaCERT, Evotec - The profit is in buying

  • Hydrogen
  • greenhydrogen
  • travel
  • Biotechnology

In the world of the financial markets, the timeless maxim applies: "The profit is in buying". This tried and tested stock market adage, which may seem trivial at first glance, is actually the key to financial success. Indeed, the price at which an investment is purchased often determines its subsequent triumph or failure long before the sale is even considered. Despite advances in technology and the complexity of markets, the basic lesson remains - buying wisely and at a well-considered price lays the foundation for profits. We have picked out three interesting candidates.

Read

Commented by Fabian Lorenz on March 26th, 2024 | 07:00 CET

Out of BioNTech and into Defence Therapeutics and Evotec shares?

  • Biotechnology
  • Pharma

The BioNTech share is currently out of steam. Although sentiment in the sector is improving, as star investor Cathie Wood recently invested in Moderna, the German biotech leader is not making any headway. The latest figures have not convinced analysts, and the price targets have even been further reduced. In contrast, the shares of Defence Therapeutics and Evotec appear to have more upside momentum. The Canadian cancer specialist has just raised new capital to develop its exciting pipeline. The Company has recently been granted a new US patent for its approach to cancer therapy. Evotec has a "Buy" recommendation. Could this mean the share is on the verge of an upward trend?

Read

Commented by Armin Schulz on March 13th, 2024 | 07:30 CET

HelloFresh, Royal Helium, Evotec - Rebounds in sight

  • Mining
  • Helium
  • Biotechnology
  • Food

Despite all the various challenges in today's world, such as geopolitical tensions or inflation, the stock market indices have managed to climb upwards. Investors are faced with a crucial question: Where is the hidden value in a market that has already broken many records? The answer could lie in those stocks that have so far stood on the sidelines of the great rally - the silent but potentially strong performers waiting for their rebound. This strategy shifts the focus away from the usual suspects who have already posted substantial gains to stocks that are ready to initiate their own rebound, potentially unlocking significant value for patient investors in the process. We have identified three such candidates.

Read

Commented by Armin Schulz on March 6th, 2024 | 07:00 CET

Cardiol Therapeutics is on the upswing - When will BioNTech and Evotec follow suit?

  • Biotechnology
  • Pharma

In the world of biotechnology, the stock market often resembles a rollercoaster ride where investors and companies need to be firmly strapped in. The volatility of biotech companies can include dizzying highs and lows driven by the research and development of new medical treatments and therapies. A single positive report of clinical trial results or regulatory approval of a breakthrough drug can send a company's share price soaring, sending investors and companies into euphoria overnight. This happened recently with Cardiol Therapeutics. When can Evotec and BioNTech announce a success?

Read